Rapid generation of sustainable HER2-specific T cell immunity in HER2 breast cancer patients using a degenerate HLA class II epitope vaccine

PURPOSE: HER2+ breast cancer patients benefit from trastuzumab-containing regimens with improved survival. Adaptive immunity, including cytotoxic T cell and antibody immunity, is critical to clinical efficacy of trastuzumab. Since helper T cells are central to the activation of these antitumor effec...

詳細記述

保存先:
書誌詳細
出版年:Clin Cancer Res
主要な著者: Knutson, Keith L., Block, Matthew S., Norton, Nadine, Erskine, Courtney L., Hobday, Timothy J., Dietz, Allan B., Padley, Douglas J., Gustafson, Michael P., Puglisi-Knutson, Danell J., Mangskau, Toni K., Chumsri, Saranya, Dueck, Amylou C., Karyampudi, Lavakumar, Wilson, Glynn, Degnim, Amy
フォーマット: Artigo
言語:Inglês
出版事項: 2019
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7056565/
https://ncbi.nlm.nih.gov/pubmed/31757875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-2123
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料